RAM
TSHA icon

Riggs Asset Management’s Taysha Gene Therapies TSHA Stock Holding History

Riggs Asset Management’s Portfolio TSHA Stock Details TSHA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-198
Closed -$398 – 687
2024
Q3 		$398 Hold
198
– – ﹤0.01% 576
2024
Q2 		$444 Hold
198
– – ﹤0.01% 555
2024
Q1 		$569 Buy
+198
New +$413 ﹤0.01% 510

Other funds holding TSHA

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Riggs Asset Management's TSHA Position: Q4 2024 in Review

Riggs Asset Management sold out of Taysha Gene Therapies (TSHA) in Q4 2024, closing a stake of 198 shares — an estimated $398 sold.

Riggs Asset Management first reported a position in TSHA in Q1 2024 and held it in 3 quarters. The position peaked at $569 in Q1 2024. 131 funds tracked by Wall St. Rank hold TSHA as of Q4 2024.

  • Riggs Asset Management reported no remaining Taysha Gene Therapies position as of Q4 2024 after selling out during the quarter.
  • Riggs Asset Management sold 198 Taysha Gene Therapies shares in Q4 2024, an estimated $398.
  • Riggs Asset Management first reported a position in Taysha Gene Therapies in Q1 2024 and held it in 3 quarters.
  • Riggs Asset Management's Taysha Gene Therapies position peaked at $569 in Q1 2024.
  • 131 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q4 2024.

Based on Riggs Asset Management's 13F filing for Q4 2024, filed 24 Jan 2025.